{
    "clinical_study": {
        "@rank": "114131", 
        "arm_group": [
            {
                "arm_group_label": "Smoking asthma on steroids", 
                "description": "Smokers with persistent asthma on background steroid therapy"
            }, 
            {
                "arm_group_label": "Smoking asthma steroid na\u00efve", 
                "description": "Smokers with persistent asthma, steroid naive"
            }, 
            {
                "arm_group_label": "asthma on steroids", 
                "description": "Non-Smokers with persistent asthma on background steroid therapy"
            }, 
            {
                "arm_group_label": "asthma, steroid na\u00efve", 
                "description": "Non-smokers with persistent asthma, steroid naive"
            }, 
            {
                "arm_group_label": "Healthy smoking", 
                "description": "Healthy smoking control subjects"
            }, 
            {
                "arm_group_label": "Healthy non-smoking", 
                "description": "Healthy non-smoking control subjects"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum sputum"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study will collect blood and sputum (phlegm) samples from subjects with asthma, smokers\n      and normal healthy subjects, to compare the biological markers of disease and inflammation."
        }, 
        "brief_title": "Sample Collection in Smoking Asthma", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (healthy subjects):\n\n          -  Male or female, between 18 and 55 years of age, inclusive.\n\n          -  no clinically significant abnormalities.\n\n          -  able to produce an adequate induced sputum sample.\n\n          -  no history of chronic respiratory disease including asthma.\n\n          -  no history of allergic symptoms e.g., allergic rhinitis, eczema.\n\n          -  No other acute illness in the 6 weeks prior to Visit 1.\n\n        Additional Inclusion Criterion for Healthy Smoking Subjects\n\n          -  Be a smoker for >/= 1 year.\n\n        Additional Inclusion Criteria (Persistent Asthmatic Subjects):\n\n          -  No contraindications to the procedures in this study.\n\n          -  Symptoms compatible with asthma for at least 6 months prior to screening\n\n          -  Pre-bronchodilator FEV1 >/=50% predicted at Visit 1.\n\n          -  clinically stable asthma for at least 6 weeks prior to Visit 1.\n\n          -  No acute illness including asthma exacerbation requiring augmentation of therapy in\n             the 6 weeks prior to Visit 1.\n\n          -  on current asthma controller therapy for >/= 6 weeks prior to Visit 1.\n\n        Additional Inclusion for Steroid Na\u00efve Asthmatics (smoking or non-smoking)\n\n          -  Must not have received a regular course of inhaled or oral corticosteroids for at\n             least 3 months prior to Visit 1.\n\n        Additional Inclusion for Smoking Asthmatics\n\n          -  Be a smoker for >/= 1 year prior to Visit 1.\n\n        Exclusion Criteria (healthy):\n\n          -  History of any clinically significant medical illness or medical disorders.\n\n          -  Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other\n             significant respiratory disorder including significant occupational or environmental\n             exposures with ongoing respiratory symptoms.\n\n          -  bronchodilator response of >/=12% and at least 200 mL from baseline or an FEV1 value\n             <85% of predicted value at Visit 1.\n\n          -  positive urine pregnancy screening result.\n\n          -  recent history (within previous 6 months) of alcohol or drug abuse.\n\n          -  Positive urine toxicology screen for substances of abuse\n\n          -  positive serology test for HIV antibodies, hepatitis B surface antigen (HBsAg), or\n             hepatitis C virus antibody (anti-HCV) at Visit 1.\n\n          -  Received an experimental antibody or biologic therapy within the 6 months prior to\n             Visit 1, or received any other experimental therapy or new investigational agent\n             within 60 days of Visit 1.\n\n          -  Is an employee or family member of the investigator, study centre or Sponsor.\n\n          -  Any condition that, in the opinion of the investigator, would complicate or\n             compromise the study, or the well-being of the subject.\n\n          -  Use of any antioxidants within 1 week of Visit 1 and throughout the study period.\n\n          -  known allergies, hypersensitivity, or intolerance to short acting \u03b2-agonists (SABA).\n\n        Additional Exclusion Criterion for Healthy Non-smoking Subjects\n\n          -  subject is a smoker (regular or irregular), or has smoked or used nicotine-containing\n             products within the 6 months prior to Visit 1.\n\n        Additional Exclusion Criteria (Persistent Asthma Subjects):\n\n          -  Diagnosis of allergic bronchopulmonary aspergillosis (ABPA), allergic\n             bronchopulmonary mycosis (ABPM), or occupational asthma.\n\n          -  Diagnosis of COPD, cystic fibrosis, or other significant respiratory disorder\n             including significant occupational or environmental exposures with ongoing\n             respiratory symptoms.\n\n          -  Use of theophylline, N-acetyl cysteine, or any other anti-oxidants within 1 week of\n             Visit 1 and throughout the study period.\n\n          -  positive test for tuberculosis at Visit 1.\n\n        Additional Exclusion Criterion for Non-smoking Asthmatic Subjects\n\n          -  subject is a smoker (regular or irregular), or has smoked or used nicotine-containing\n             products within the 6 months prior to Visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects will be selected by advertisements from the general population and primary care."
            }
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676467", 
            "org_study_id": "ENA002"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Harrow", 
                    "country": "United Kingdom", 
                    "state": "Middlesex", 
                    "zip": "HA1 3UJ"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "6", 
        "official_title": "A Sample Collection Protocol for Disease Profiling of Smoking Asthma.", 
        "overall_official": {
            "affiliation": "Respivert Ltd", 
            "last_name": "Dr Garth Rapeport", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Measurement of biomarkers of inflammation, including but not limited to: TNF\u03b1, IL-8, IFN\u03b3, IP10 and eotaxin in sputum supernatant and serum will be collected and measured only once, at Visit 2 (Day 10).", 
                "measure": "Sputum and serum biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "Sputum cell count (total cells, differentials and absolute number) at Visit 2 (Day 10).", 
                "measure": "Sputum cell count", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676467"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Respivert Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Respivert Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}